Results 111 to 120 of about 18,680 (231)

Translating gut microbiome research into therapies for type 1 diabetes

Experimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok, Max Nieuwdorp, Elena Rampanelli   +2 more
wiley   +1 more source

Design, synthesis, and biological activity of novel pomalidomide linked with diphenylcarbamide derivatives

Heterocyclic Communications, 2022
Sun Bin, Liu Xiaofei, Ji Tao, Zhan Xiaoguang, Mao Longfei, Deng Peng, Shi Lin   +6 more
doaj   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
The graphical abstract illustrates how microbiome‐derived indoles activate the aryl hydrocarbon receptor to restore the intestinal barrier. The picture contrasts the “leaky gut” state with the restored homeostasis achieved through AMPK, Nrf2, and IL‐22 signaling.
Mohammad Ali Mahdiabadi, Asma Moghaddam, Nafiseh Erfanian   +2 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Investigation of IDO1 and TDO2 expression in breast tumors by immunohistochemistry and real-time polymerase chain reaction methods

Biotechnology & Biotechnological Equipment
Although diagnostic and therapeutic advances have been made in the treatment of breast cancer, the challenge of effectively controlling tumor progression persists.
Gülden Yıldız, Hüseyin Büyükbayram, Ulaş Alabalik, Ayşe Nur Keleş   +3 more
doaj   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

IDO1 inhibits ferroptosis by regulating FTO-mediated m6A methylation and SLC7A11 mRNA stability during glioblastoma progression

Cell Death Discovery
Indoleamine 2, 3-dioxygenase 1 (IDO1) has been recognized as an enzyme involved in tryptophan catabolism with immunosuppressive ability. This study determined to investigate the impact of IDO1 on glioblastoma multiforme (GBM) cells.
Qianting Tian, Guixue Dan, Xuyan Wang, Jiamei Zhu, Chaochun Chen, Dekun Tang, Ziming Wang, Dan Chen, Shan Lei, Chao Yang, Houmei Wang, Bing Guo, Bangming Jin, Tengxiang Chen, Lei Tang   +14 more
doaj   +1 more source

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

Advanced Science, Volume 13, Issue 51, 14 September 2026.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu, Shutao Zhang, Yumin Lin, Juyang Jiao, Zhiwei Fu, Qimin Hong, Ziyi Zhao, Xinhua Qu, Fei Su, Bing Yue   +9 more
wiley   +1 more source

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer

MedComm
Indoleamine 2,3‐dioxygenase 1 (IDO1), the key enzyme in the catabolism of the essential amino acid tryptophan (Trp) through kynurenine pathway, induces immune tolerance and is considered as a critical immune checkpoint, but its impacts as a metabolism ...
Heng Liang, Jiani Zhan, Yunqiu Chen, Zikang Xing, Zhen Ning Tony He, Yuying Liu, Xuewen Li, Yijia Chen, Zhiyao Li, Chunxiang Kuang, Dan Yang, Qing Yang   +11 more
doaj   +1 more source